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Abstract 
Tau accumulation is a key neuropathological feature for diagnosis of Alzheimer’s 
disease (AD). The density and spread of tau neurofibrillary tangles in the AD’s brain 
cases correspond and indicate to the progression and severity level of the disease. Positron 
emission tomography (PET) imaging, a sensitive and non-invasive imaging technique, is 
a powerful tool for detection and quantification of accumulated tau protein in the brain. 
Several tau PET tracers have been discovered and tested in humans. Most of them, 
however, demonstrated some limitations such as off-target binding, defluorination, and 
low yield production. [18F]THK-5351, the previously developed as the first generation of 
tau PET tracer, have been revealed to show an off-target binding to monoamine oxidase 
B (MAO-B). To reduce the off-target binding of the previous tracer, [18F]THK-5351, this 
thesis proposed the new heteroaromatic compounds as selective tau PET tracers with the 
preferable properties for brain PET imaging.  
Based on the structure of MK-6240, a 3-pyrrolopyridinyl-isoquinoline amine 
derivative, which shows high affinity for NFTs and little off-target binding, exhibits fast 
brain penetration and kinetics and absence of brain-permeable metabolites. The 
optimization of [18F]THK-5351 had been performed by modified the structure based on 
2-pyrrolopyridinyl-quinoline derivatives (PPQs). The core structure of PPQ derivatives 
was synthesized mainly using the Buchwald-Hartwig amination coupling reaction. All 
derivatives were evaluated for binding affinity towards tau and MAO-B by in vitro 
competitive binding assay.  
The PPQ derivatives were synthesized, with yields of 49–84%. In vitro 
competitive binding assay revealed that two novel PPQ derivatives, PPQ8 and PPQ9, 
demonstrated high binding affinity for tau (IC50 = 4.9 and 6.9 nM, respectively). The 
radiosynthesis of [18F]PPQ8 and [18F]PPQ9 yielded 1.4% and 50.1% isolated non-decay 
corrected radiochemical yield, respectively, with >99% radiochemical purity. The molar 
radioactivities of [18F]PPQ8 and [18F]PPQ9 were 16.9 and 64.8 GBq/µmol, respectively.  
Characterization of [18F]PPQ8 and [18F]PPQ9 by in vitro autoradiography of 
postmortem AD brain sections revealed that these tracers were selective for tau in AD 
brain sections without major off-target binding (Figure 1). However, these candidates did 
not exhibit a good pharmacokinetics in mice (Figure 2). Therefore, further modification 
and optimization of these derivatives were required to improve pharmacokinetics for 
potent tau PET imaging tracers is required (P. Lerdsirisuk et al. Nuclear Medicine and 
Biology. 2020). 
 
Figure 1. The autoradiography of [18F]PPQ8 and [18F]PPQ9 in comparison to [18F]THK-5351 
and [18F]florbetaben (amyloid PET tracer). 
 
Figure 2. The structure and pharmacokinetic profile of [18F]PPQ8 and [18F]PPQ9 in mice. 
For further optimization, the core structure of PPQ5 was modified to overcome 
the off-target binding to MAO-B and provide the suitable pharmacokinetic. The newly 
designed derivatives were successfully synthesized and evaluated the binding affinity for 
tau and MAO-B by in vitro competitive binding assay using [3H]MK-6240 (tau ligand) 
and [3H]THK-5351 (MAO-B ligand), respectively. Through the analysis of the structure-
activity relationship among the new derivatives, the imidazopyridine amine was found to 
be a novel core structure suitable for imaging tau aggregates in human AD due to quite a 
low binding affinity for MAO-B. Among the derivatives, N12 was selected as a promising 
candidate for tau-selective PET tracers (IC50 = 0.8 nM for tau, >1,000 nM for beta-
amyloid, MAO-A, and MAO-B). 
[18F]N12 was successfully radiosynthesized in moderate radiochemical yields 
with 99% radiochemical purity. In vitro autoradiogram of the AD brain sections with 
[18F]N12 displayed an intense laminar binding to the neocortex sections with no off-target 
binding. The distribution of radioactivity was well consistent with the staining of 
accumulated tau proteins on AD brain tissue (Figure 3). Additionally, [18F]N12 showed 
high initial brain uptake (4.35 ± 0.57 %ID/g at 2 min post injection) and rapid clearance 
(0.35 ± 0.06 %ID/g at 30 min post injection) suitable for brain PET imaging. Preferably, 
the radiolabeled metabolites of [18F]N12 did not penetrate the blood-brain barrier in 
mouse. These results suggested that [18F]N12, which is now called [18F]SNFT-1, is a 
promising candidates as a selective tau PET tracer without off-target binding. 
 
Figure 3. The autoradiography of [18F]N12, [18F]flortaucipir (tau ligand), and [18F]florbetaben 
(amyloid ligand) in subcortical and cortical regions of the AD brain and histological staining for 
tau (AT8) and amyloid-β (6F/3D). (WM = white matter). 
 
Figure 4. Pharmacokinetic profile of [18F]N12 (SNFT-1) in mice . 
